AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2014
Dec 2, 2014
31580_dirs_2014-12-02_39aae2c8-12d5-47bc-b12a-84c6c71e3a2a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2014-12-01
Reporting Person: Schenkein David P (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-12-01 | Common stock | S | 6500 | $97.03 | Disposed | 236272 | Indirect |
| 2014-12-01 | Common stock | S | 6500 | $97.03 | Disposed | 118272 | Indirect |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $95.00 to $101.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F4: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.